AKBA · Akebia Therapeutics, Inc. · Metrics
$0.42
+0.01 (+3.28%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$117.26M
Shares
277.66M
Volume · Nov 19
2.75M
Avg daily vol (3M)
8.17M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
AKBA metrics
84 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$0.42
Market cap
$117.26M
Price action
23 metricsPrice change (1W)
-15.2%
Price change (30D)
-27.8%
Price change (3M)
-54.0%
Price change (6M)
-58.6%
Price change (YTD)
-73.8%
Price change (1Y)
-73.4%
Trailing year
Price change (5Y)
-84.8%
52-week high
$1.70
52-week low
$0.40
Change from 52-week high
-75.2%
Change from 52-week low
+5.5%
Annualized volatility
89.9%
Annualized volatility (3M)
128.6%
Implied volatility (30D)
149.3%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.6
RSI (14D)
34.9
Price vs SMA 50
-41.9%
Price vs SMA 200
-61.1%
Avg volume (3M)
8.17M
Relative volume
0.3
Average dollar volume
$6.30M
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
277.66M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.0×
reciprocal yield 2,383.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.6×
reciprocal yield 168.2%
P / book
5.8
reciprocal yield 17.4%
FCF yield
11.8%
TTM · current market cap
Buyback yield
—
P / FCF
8.5
reciprocal yield 11.8%
P / operating cash flow
7.4
reciprocal yield 13.5%
Earnings yield
-38.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.6×
reciprocal yield 61.1%
EV / revenue historical average (5Y)
1.3×
reciprocal yield 74.9%
EV / EBIT historical average (3Y)
239.9×
reciprocal yield 0.4%
EV / EBIT historical average (5Y)
239.9×
reciprocal yield 0.4%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-11-05
Profitability
9 metricsGross margin
78.9%
Operating margin
-15.7%
Trailing 12 months
Net margin
-22.6%
Gross profit (TTM)
$155.59M
Operating profit (TTM)
−$31.04M
Net income (TTM)
−$44.56M
Trailing 12 months
Diluted EPS (TTM)
$-0.16
FCF margin
7.0%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-37.2%
Year over year
Net income growth YoY
-2,758.1%
Revenue (TTM)
$197.20M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.9%
Year over year · more shares
Revenue CAGR (3Y)
-6.9%
Revenue CAGR (5Y)
-4.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-218.8%
Return on assets
-13.0%
Debt / equity
2.5
Current ratio
1.4
EBITDA (TTM)
—
Free cash flow (TTM)
$13.86M
Quick ratio
1.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$108.98M
Latest balance sheet
Cash & equivalents
$159.25M
Total assets
$342.13M
Total debt
$50.27M
Cash flow & spend
7 metricsOperating cash flow (TTM)
$15.78M
Capital expenditures (TTM)
$1.92M
R&D (TTM)
$71.70M
SG&A (TTM)
$108.23M
Stock compensation (TTM)
$12.89M
R&D / revenue
36.4%
Stock compensation / revenue
6.5%
Ownership (13F)
9 metrics13F filers
157
13F filer change QoQ
-13
Institutional ownership
39.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
10.2%
Private-fund adviser ownership
10.1%
Active holders' share change QoQ
+0.2%
Holder tenure
11.7
Price vs estimated holder cost
-42.1%
Ownership (registered funds)
1 metricsIndex-fund ownership
13.1%
Short interest
3 metricsShort interest
9.8%
Latest settlement · 3.0 days to cover
Days to cover
3.0d
Short-squeeze score
62 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1517022
CUSIP
00972D105
13F (30d)
157 filings
140 filers
Visit website
Investor relations